VANCOUVER, British Columbia — Conditions like diabetes and dementia are common in patients who are admitted to long-term care facilities, but aggressive management of these conditions […]

LONDON (Reuters) -Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its […]

The decision to prescribe a compounded or brand-name glucagon-like peptide 1 (GLP-1) medication for obesity treatment was never simple, but recent developments have complicated it further. […]

CHICAGO — New research is illuminating the long-term health consequences faced by patients with thyroid cancer in areas related to fertility, bone health, and cardiovascular disease. […]

SAN ANTONIO — Semaglutide 2.4 mg (Wegovy) was associated with a 22% reduction in annual medical costs in people with overweight/obesity and heart failure, new research […]

(Reuters) -Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding […]

SAN ANTONIO — Weight loss treatments aren’t reaching many of the people who need them most due to coverage barriers, new data suggested. Findings from three […]

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off […]

The recent US Food and Drug Administration (FDA) clearance of two over-the-counter (OTC) continuous glucose monitors (CGMs) — Dexcom’s Stelo and Abbott’s Lingo — has sparked interest […]